Abstract
TheRET proto-oncogene has not only conclusively been identified as responsible for the three subtypes of the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN-2) but also shown to be involved in the molecular evolution of sporadic medullary and papillary thyroid carcinoma as well as Hirschsprung’s disease. A variety of recent studies have elucidated the pathophysiological mechanisms leading to neoplastic disease and we now understand that dominant activating germline mutations lead to MEN-2A, MEN-2B, and familial MTC; somatic mutations to sporadic medullary thyroid carcinoma;RET rearrangements to papillary thyroid carcinoma; and inactivating alterations to Hirschsprung's disease. The clinical significance, however, ofRET alterations especially in sporadic thyroid tumors is still controversial and therapeutic concepts in MEN-2 gene carriers only start to emerge. This article is a short summary of the recent findings on the structure and physiology of theRET proto-oncogene and its role in familial and sporadic thyroid cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lloyd RV. RET proto-oncogene mutations and rearrangements in endocrine diseases [comment]. Am J Pathol 147:1539–1544, 1995.
Durbec P, Marcos GC, Kilkenny C, Grigoriou M, Wartiowaara K, Suvanto P, Smith D, Ponder B, Costantini F, Saarma M, Sariola H, Pachnis V. GDNF signalling through the Ret receptor tyrosine kinase. Nature 381:789–793, 1996.
Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj BA, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A. Characterization of a multicomponent receptor for GDNF [see comments]. Nature 382:80–83, 1996.
Eng C. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 335:943–951, 1996.
De Lellis RA. Multiple endocrine neoplasia syndromes revisited. Clinical, morphologic and molecular features. Lab Invest 72:494–505, 1995.
Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WKF, Matias-Guiu X, Heitz PU. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 81:2041–2046, 1996.
Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BA. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56:2167–2170, 1996.
Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80:3088–3090, 1995.
Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol Oxf 44:249–257, 1996.
Komminoth P, Kunz EK, Hiort O, Matias-Guiu X, Christiansen G, Roth J, Heitz PU. Analysis of RET proto-oncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer 76:479–489, 1995.
Komminoth P, Muletta-Feurer S, Saremaslani P, Kunz EK, Matias-Guiu X, Hiort O, Schroder S, Seelentag WKF, Roth J, Heitz PU. Molecular diagnosis of multiple endocrine neoplasia (MEN) in paraffin-embedded specimens. Endocr Pathol 6:267–278, 1995.
Jhiang SM, Mazzaferri EL. The ret PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 123:331–337, 1994.
Fugazzola L, Pierotti MA, Vigano E, Pacini F, Vorontsova TV, Bongarzone I. Molecular and biochemical analysis of RET/PTC4 a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene 13:1093–1097, 1996.
Bongarzone I, Fugazzola L, Vigneri P, Mariani L, Mondellini P, Pacini F, Basolo F, Pinchera A, Pilotti S, Pierotti MA. Age-related activation of the tyrosine kinase receptor proto-oncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 81:2006–2009, 1996.
Viglietto G, Chiappetta G, Martinez Tello F, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M, Fusco A. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 11:1207–1210, 1995.
Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL. ret/PTC-1, −2, and −3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab 81: 3360–3365, 1996.
Carlomagno F, De VG, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, Kraus MH, Di Fiore P, Fusco A, Santoro M. Molecular heterogeneity of RET loss of function in Hirschsprung's disease. Embo J 15:2717–2725, 1996.
Mulligan LM, Eng C, Attié T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, Venter DJ, Munnich A, Ponder BAJ. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Human Molecular Genetics 3:2163–2167, 1994.
Dahia PLM, Toledo SPA, Mulligan LM, Maher ER, Grossman AB, Eng C. Mutation analysis of glial cell line-derived neurotrophic factor (GDNF), a ligand for the RET/GDNF receptor α complex, in sporadic phaeochromocytomas. Cancer Res 57:310–313, 1997.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Komminoth, P. RET proto-oncogene and thyroid cancer. Endocr Pathol 8, 235–239 (1997). https://doi.org/10.1007/BF02738791
Issue Date:
DOI: https://doi.org/10.1007/BF02738791